Use of Sequenom's MassARRAY System Leads to Significant Scientific Advances in Understanding Cancer, Diabetes and Drug-Resistant MalariaSAN DIEGO--(BUSINESS WIRE)--Mar 14, 2007 - Sequenom, Inc. (NASDAQ: SQNM) today announced that its MassARRAY(R) technology and iPLEX(TM) assay were used by leading scientists from international research institutions and, in independent studies, significantly advanced the understanding of cancer, diabetes and drug-resistant malaria. Results from several of these studies were published in highly recognized peer-reviewed journals as follows:
-- In "High-Throughput Oncogene Mutation Profiling in Human Cancer," published in the February issue of Nature Genetics, the authors, led by scientists at Harvard and MIT, recognizing the difficulty in identifying critical genetic events across a spectrum of human tumors with enough sensitivity and scalability, utilized MassARRAY technology to assay 238 known oncogene mutations across 1,000 human tumor samples. The results enable researchers to simultaneously interrogate mutations in multiple cancer genes to guide cancer classification and therapeutic intervention.
-- In "A Genome-wide Association Study Identifies Novel Risk Loci for Type 2 Diabetes," published in the February issue of Nature, the authors, led by scientists from McGill University and Pasteur Institute, studied the association between type 2 diabetes, environmental factors and a combination of genetic variants, most of which were previously unknown. Fast track SNP Marker confirmation was performed using Sequenom's iPLEX assay.
-- In "A Common Coding Variant in CASP8 is Associated with Breast Cancer Risk," published in the February issue of Nature Genetics, the authors, led by scientists at Sheffield University Medical School, University of Cambridge and National Cancer Institute, found evidence of an association between breast cancer and CASP8 D302H. Mutations such as BRCA1 and 2 account for less than 25% of the familial risk of breast cancer. In this study, the researchers demonstrate that common breast cancer susceptibility alleles with small individual effects on risk can be identified, so that combinations of lower-penetrance variants can be used to assess much of the remaining genetic risk. The consortium involved 20 collaborating research groups, many of which used Sequenom MassARRAY technology in their contributions.
-- In "A Genome-wide Map of Diversity in Plasmodium Falciparum," published in the February issue of in Nature Genetics, the authors, led by scientists at Harvard and MIT, reported their finding that the genetic variation of the malaria parasite has allowed it to overcome chemotherapeutic agents, vaccines, and other control strategies, and thus has remained a leading cause of global morbidity and mortality. The SNP genotyping was performed using the MassARRAY platform.
Sequenom is committed to providing the best genetic analysis products that translate genomic science into superior solutions for non-invasive prenatal testing, biomedical research, molecular medicine and agricultural applications. The Company's proprietary MassARRAY system is a high-performance DNA analysis platform that efficiently and precisely measures the amount of genetic target material and variations therein. The system is able to deliver reliable and specific data from complex biological samples and from genetic target material that is only available in trace amounts. The Company has exclusively licensed intellectual property rights for the development and commercialization of non-invasive prenatal genetic tests for use with the MassARRAY system and other platforms.
Sequenom(R) and MassARRAY(R) and iPLEX(TM) are trademarks of SEQUENOM, Inc.
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the Company's intentions to develop and commercialize non-invasive prenatal genetic tests, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with the Company's technologies, market acceptance of and demand for the Company's products, reliance upon the collaborative efforts of others, product development and commercialization, and other risks detailed from time to time in the Company's SEC reports, including the Company's Annual Report on Form 10-K for the year ended December 31, 2005 and subsequent periodic reports. These forward-looking statements are based on current information that is likely to change and speak only as of the date hereof. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and Sequenom undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.
John Sharp, VP, Finance, 858-202-9032
Investor Relations Contact
Lippert/Heilshorn & Associates
Zachary Bryant, firstname.lastname@example.org
Jody Cain, email@example.com
Posted: March 2007